Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat diseases. The deals have a combined value of around $3 billion. Isomorphic will receive $45 million upfront […]
© 2023 TechCrunch. All rights reserved. For personal use only.
Source : Isomorphic inks deals with Eli Lilly and Novartis for drug discovery
